[ad_1]
Currently, more than 760 cell therapies are under development. Most cell therapies are in the preclinical phase, followed by Phase I clinical trials. Currently, more than 20 cell therapies are available on the market. The United States has a maximum number of commercial cell threapies.
Download the report:
https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php
Global Market for Cell Therapy, Clinical Trials, Treatment Prices, and Opportunity Snapshot 2026 " Highlights of the report:
- Opportunity of the global market for cell therapy: more than 35 billion US dollars by 2026
- Clinical trial on cell therapy by indication, society and country
- Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
- Cell therapies marketed worldwide: 25 cell therapies
- Maximum Number of Cell Therapies Marketed in the United States: 15 Therapies
- Price and product badysis by region / country
- Regional Analysis of the Cell Therapy Market
Contents
- Overview of cell therapy
1.1 Introduction to Cell Therapy
1.2 History and evolution of cell therapy
- Types of cell therapy
2.1 Allogeneic cell therapy
2.2 Autologous Cell Therapy
2.3 Human embryonic stem cell therapy
2.4 Neural stem cell therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic stem cell transplantation
- Mechanism of therapeutic action in cell therapy
- Manufacture of cellular therapies
4.1 Cell Therapy Manufacturing Models
4.2 Facilities for Good Manufacturing Practices
- Benefits of Cell Therapy versus Conventional Therapy
5.1 Anti-aging with cell therapy
5.2 Treat other diseases with cell therapy
- Personalized cell therapy
6.1 Overview of personalized cell therapy
6.2 Custom Cell Therapy Using Epigenetic Tools
6.3 Personalized cell therapy through mesenchymal stem cells
6.4 Treatment of Parkinson's Disease via IPSCs
6.5 Case Study: Custom Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells and Leukocyte Platelet-rich Fibrin
- Application of therapeutic cell therapy
7.1 Cardiovascular disease
7.2 Neurological disorders
7.3 Inflammatory diseases
7.4 diabetes
7.5 Cancer
- Global Perspectives of the Cell Therapy Market
8.1 Current Market Scenario
8.2 Market for cell therapy by cell source
8.2.1 Induced Pluripotent Stem Cells (IPSC)
8.2.2 Bone marrow
8.2.3 Cells derived from umbilical cord blood
8.3 Overview of the Global Cell Therapy Clinical Pipeline (Company, Indication, Region)
- US – Dosage and Cost Analysis of Cell Therapy
9.1 Allocord
9.2 Laviv
9.3 Maci
9.4 Clevecord
9.5 Hemacord
9.6 Ducord
9.7 Provenge
9.8 HPC, cord blood (Clinimmune Labs, Cord Blood Bank of the University of Colorado)
9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
9.10 HPC, Blood Blood
9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
9.12 Gintuit
9.13 Kymriah *
9.14 Yescarta *
9.15 Carticel
- South Korea – Dosage and Cost Analysis of Cell Therapy
10.1 Cartistem
10.2 Chondron
10.3 KeraHeal
10.4 Cellgram
10.5 Cure Injection of the skin
- Australia, Europe and Japan – Dosage Analysis and Cell Therapy Costs
11.1 Holoclar (Europe)
11.2 Yescarta (EU)
11.3 Kymriah (EU)
11.4 Temcell HS (Japan)
11.5 Chondrocytes-T-Ortho-ACI (Australia)
- Cell Therapy Market Trends: Geographically
12.1 US
12.2 South Korea
12.3 Europe
12.4 Japan
12.5 China
12.6 Rest of the world
12.6.1 Africa
12.6.2 Middle East
12.6.3 South America
- Progress in Cell Therapy
13.1 Progress of pharmacotherapy in chronic lymphocytic leukemia
13.2 Progress in the prevention and treatment of cytomegalovirus infections
13.3 Stem Cell Therapy for the Treatment of Parkinson's Disease
13.4 Stem Cell Therapy for the Treatment of Alzheimer's Disease
13.5 Treatment of rheumatoid arthritis with stem cell therapy
13.6 Role of stem cell therapy in the treatment of infertility
13.7 Stem cells for eye diseases
13.8 Cell therapy of stroke and angina pectoris
13.9 Stem cell therapy to improve wrinkles and acne scars
- Treg Cells – The Next Step in Cell Therapy
14.1 Introduction to the Treg cell
14.2 Isolation and expansion of the Treg cell
14.3 Mechanism of action
14.4 Clinical Trials of Treg Cell Therapy
14.4.1 Adoptive Cell Therapy of Treg Cells to Prevent GvHD
14.4.2 Adoptive cell therapy of polyclonal and alloantigen-specific Treg cells to prevent rejection of solid organ transplants
14.5 Treg Cell Therapy for the Treatment of Autoinflammatory and Autoimmune Diseases
14.5.1 Inflammatory bowel disease
14.5.2 Systemic lupus erythematosus
14.5.3 Autoimmune hepatitis
14.5.4 Pemphigus Vulgaris
14.5.5 Allergy and asthma
14.6 Future Perspectives of Treg Cell Therapy
- Dynamics of the global market for cell therapy
15.1 Market factors
15.2 Business Challenges
- Future perspectives of the global market for cell therapy
- Clinical information on cell therapies marketed by company and indication
17.1 Tisagenlecleucel (Kymriah)
17.2 Axicabtagene Ciloleucel (Yescarta)
17.3 Allogeneic keratinocytes and fibroblasts in culture (Gintuit)
17.4 Fat Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
17.5 Tonogenchoncel-L (INVOSSA-K inj)
17.6 Mesenchymal Stem Cell Therapies (Stempeucel)
17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
17.8 Sipuleucel-T (Provenge)
17.9 Autologous mesenchymal stem cell therapy – Pharmicell
17.10 Chondrocytes in autologous culture (MACI)
17.11 Chondrocytes in autologous culture (Chondrotransplant DISC)
17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
17.13 Nalotimagene Carmaleucel (Zalmoxis)
17.14 Mesenchymal stem cell therapy for cartilage repair (Cartistem)
17.15 Autologous Chondrocyte Implant – TETEC
17.16 Autologous stem cell therapy derived from muscle (MyoCell)
17.17 Replacement of human skin (CellSpray)
17.18 Leukocyte Cell Therapy (CureXcell)
17.19 Implant of chondrocytes in autologous culture (Carticel)
17.20 Azficel-T (Laviv)
17.21 Chondrocytes in autologous culture (CHONDRON)
17.22 Autologous chondrocytes (BioCart)
17.23 Amniotic Cell Therapy (NuCel)
17.24 Killer cells induced by cytokines activated by dendritic cells – Shanghai Jia Fu Medical
17.25 Autologous myoblasts and fibroblasts (Urocell)
- Global Cell Therapy Clinical Pipeline by Company, Indication and Phase
18.1 Research
18.2 preclinical
18.3 clinic
18.4 phase 0
18.5 Phase I
18.6 Phase I / II
18.7 Phase II
18.8 Phase II / III
18.9 Phase III
18.10 Pre-registration
18.11 Registered
- Competitive landscape
19.1 Athersys Inc.
19.2 Baxter Healthcare Corporation
19.3 Bone Therapy
19.4 Celgene Corporation
19.5 Cell Medica
19.6 Therapeutic Cellerant
19.7 FibrocellScinence
19.8 Genzyme Corporation
19.9 Green Cross Cell
7:10 pm Histogenics Corporation
19.11 Intrexon Corporation
19.12 Intercytex
19.13 organic products ISTO
19.14 macrocure
19:15 Mesoblast
19.16 molmed
19.17 Nuo Therapeutics Inc
19.18 OmniCyte
19.19 Opexa Therapeutics
19.20 Organogenesis
19.21 Pharmicell
19.22 TCA Cell Therapy
19.23 Stem Cell Inc.
19.24 Teva Pharmaceuticals
Tigenix
19.26 Vericel Corporation
Contact:
Neeraj Chawla
Research Director
+ 91-9810410366
[ad_2]
Source link
